AtriCure makes surgical devices for treating atrial fibrillation and managing pain after surgery, sold mainly to medical centers. ATRC reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for ATRC are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ATRC is in one of them and how their past ATRC trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About AtriCure
AtriCure makes surgical devices for treating atrial fibrillation, an irregular heartbeat, and for managing pain after surgery. Its ablation and left atrial appendage products, including the AtriClip system and the EPi-Sense ablation system, are used by surgeons and electrophysiologists during heart surgery and minimally invasive procedures. The company also sells cryo probes that freeze nerves to provide temporary relief from pain after cardiac, thoracic and amputation surgery. Its products are sold to medical centers through a direct sales force and distributors, and the company is based in Mason, Ohio.
